Patents by Inventor Mark Allan WOLF

Mark Allan WOLF has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11471436
    Abstract: A compound represented by general formula (I) wherein all the symbols are as defined in the specification has a selective S1P5 receptor agonist activity due to having a linker from a phenyl group to a cyclic substituent in a dihydronaphthalene skeleton; i.e., due to having a short linker of one atom or less as L in general formula (I), and can therefore serve as an agent for treating S1P5-mediated disease, e. g., neurodegenerative disease such as schizophrenia.
    Type: Grant
    Filed: December 3, 2015
    Date of Patent: October 18, 2022
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Kensuke Kusumi, Haruto Kurata, Atsushi Naganawa, Yasuyo Kodera, Yuichi Inagaki, Hiroya Takizawa, Mark Allan Wolf, Joseph Raker
  • Patent number: 11459322
    Abstract: The present disclosure relates to indole compounds and pharmaceutical compositions thereof, and their use in stimulating the immune system of patients in need thereof and in treating cancer.
    Type: Grant
    Filed: November 19, 2018
    Date of Patent: October 4, 2022
    Assignee: ARIAGEN, INC.
    Inventors: Peter Colabuono, Graham Johnson, David Douglas Manning, Mark Allan Wolf
  • Patent number: 11427576
    Abstract: The present disclosure relates to indole compounds and pharmaceutical compositions thereof, and their use in stimulating the immune system of patients in need thereof and in treating cancer.
    Type: Grant
    Filed: February 18, 2021
    Date of Patent: August 30, 2022
    Assignee: ARIAGEN, INC.
    Inventors: Peter Colabuono, Graham Johnson, David Douglas Manning, Mark Allan Wolf
  • Publication number: 20210179604
    Abstract: The present disclosure relates to indole compounds and pharmaceutical compositions thereof, and their use in stimulating the immune system of patients in need thereof and in treating cancer.
    Type: Application
    Filed: February 18, 2021
    Publication date: June 17, 2021
    Applicant: ARIAGEN, INC.
    Inventors: Peter Colabuono, Graham Johnson, David Douglas Manning, Mark Allan Wolf
  • Publication number: 20200354353
    Abstract: The present disclosure relates to indole compounds and pharmaceutical compositions thereof, and their use in stimulating the immune system of patients in need thereof and in treating cancer.
    Type: Application
    Filed: November 19, 2018
    Publication date: November 12, 2020
    Applicant: ARIAGEN, INC.
    Inventors: Peter Colabuono, Graham Johnson, David Douglas Manning, Mark Allan Wolf
  • Publication number: 20170327439
    Abstract: A compound represented by general formula (I) (wherein, all the symbols are as defined in the specification) has a selective S1P5 receptor agonist activity due to having a linker from a phenyl group to a cyclic substituent in a dihydronaphthalene skeleton; .i.e., due to having a short linker of one atom or less as L in general formula (I), and can therefore serve as an agent for treating S1P5-mediated disease, e.g., neurodegenerative disease such as schizophrenia.
    Type: Application
    Filed: December 3, 2014
    Publication date: November 16, 2017
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Kensuke KUSUMI, Haruto KURATA, Atsushi NAGANAWA, Yasuyo KODERA, Yuichi INAGAKI, Hiroya TAKIZAWA, Mark Allan WOLF, Joseph RAKER
  • Patent number: 9586967
    Abstract: A compound represented by the general formula (1) has a pyridone ring structure introduced into a pyrrolo pyrimidine skeleton, so that the compound has a strong Axl inhibitory activity. Consequently, the compound can be used as a therapeutic agent for Axl-related diseases including cancers such as acute myeloid leukemia, melanoma, breast cancer, pancreatic cancer, and glioma, kidney diseases, immune system diseases, and circulatory system diseases.
    Type: Grant
    Filed: November 6, 2014
    Date of Patent: March 7, 2017
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Takayuki Inukai, Jun Takeuchi, Tomoko Yasuhiro, Mark Allan Wolf, Vijay Dattaram Pawar, Anjan Chakrabarti, Santhosh Kumar Chittimalla
  • Publication number: 20160264579
    Abstract: A compound represented by the general formula (1) has a pyridone ring structure introduced into a pyrrolo pyrimidine skeleton, so that the compound has a strong Axl inhibitory activity. Consequently, the compound can be used as a therapeutic agent for Axl-related diseases including cancers such as acute myeloid leukemia, melanoma, breast cancer, pancreatic cancer, and glioma, kidney diseases, immune system diseases, and circulatory system diseases.
    Type: Application
    Filed: November 6, 2014
    Publication date: September 15, 2016
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Takayuki INUKAI, Jun TAKEUCHI, Tomoko YASUHIRO, Mark Allan WOLF, Vijay Dattaram PAWAR, Anjan CHAKRABARTI, Santhosh Kumar CHITTIMALLA